{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=EBR%2FGZR",
    "query": {
      "intervention": "EBR/GZR"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 4,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-08T07:55:13.221Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT03585101",
      "title": "A Single-arm Evaluation of the Effect of HCV Treatment on Cardiovascular Disease Risk",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Hepatitis C"
      ],
      "interventions": [
        {
          "name": "Elbasvir/grazoprevir",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of California, Los Angeles",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 0,
      "start_date": "2018-08",
      "completion_date": "2020-04",
      "has_results": false,
      "last_update_posted_date": "2018-08-07",
      "last_synced_at": "2026-09-08T07:55:13.221Z",
      "location_count": 1,
      "location_summary": "Los Angeles, California",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03585101"
    },
    {
      "nct_id": "NCT03221582",
      "title": "Impact of Hepatitis C Therapy and Bone Health",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Human Immunodeficiency Virus",
        "Hepatitis C"
      ],
      "interventions": [
        {
          "name": "EBR/GZR",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Dallas VA Medical Center",
      "sponsor_class": "FED",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "40 Years and older · Male only"
      },
      "enrollment_count": 6,
      "start_date": "2017-08-28",
      "completion_date": "2018-11-30",
      "has_results": false,
      "last_update_posted_date": "2019-08-19",
      "last_synced_at": "2026-09-08T07:55:13.221Z",
      "location_count": 1,
      "location_summary": "Dallas, Texas",
      "locations": [
        {
          "city": "Dallas",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03221582"
    },
    {
      "nct_id": "NCT03379506",
      "title": "Elbasvir (EBR)/Grazoprevir (GZR) in Pediatric Participants With Chronic Hepatitis C Infection (MK-5172-079)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "HCV Infection"
      ],
      "interventions": [
        {
          "name": "EBR/GZR FDC Tablet",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Grazoprevir Oral Granules",
          "type": "DRUG"
        },
        {
          "name": "Elbasvir Oral Granules",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Merck Sharp & Dohme LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "3 Years",
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "3 Years to 17 Years"
      },
      "enrollment_count": 57,
      "start_date": "2018-01-25",
      "completion_date": "2020-07-23",
      "has_results": true,
      "last_update_posted_date": "2023-05-31",
      "last_synced_at": "2026-09-08T07:55:13.221Z",
      "location_count": 8,
      "location_summary": "San Francisco, California • Orlando, Florida • Atlanta, Georgia + 5 more",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Orlando",
          "state": "Florida"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Cincinnati",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03379506"
    },
    {
      "nct_id": "NCT02786537",
      "title": "Study of Oral Treatments for Hepatitis C",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Chronic Hepatitis C"
      ],
      "interventions": [
        {
          "name": "SOF/LDV (sofosbuvir/ledipasvir)",
          "type": "DRUG"
        },
        {
          "name": "PrOD (ombitasvir/paritaprevir/ritonavir with dasabuvir) (Phase 1 only)",
          "type": "DRUG"
        },
        {
          "name": "EBR/GZR (elbasvir/grazoprevir)",
          "type": "DRUG"
        },
        {
          "name": "Ribavirin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Florida",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 1275,
      "start_date": "2016-06",
      "completion_date": "2020-09-02",
      "has_results": true,
      "last_update_posted_date": "2021-12-06",
      "last_synced_at": "2026-09-08T07:55:13.221Z",
      "location_count": 38,
      "location_summary": "Little Rock, Arkansas • Palo Alto, California • San Diego, California + 27 more",
      "locations": [
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02786537"
    }
  ]
}